Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule

Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), D. J. Th. Wagener(Radboud University Nijmegen), Olaf van Tellingen(Dutch Cancer Society), J. Kerger(Institut Jules Bordet), L Van Manen(Radboud University Nijmegen), Y. Groot, Martine Piccart(Université Libre de Bruxelles), Jaap Verweij(Deutz (Germany)), J. Wanders(Eisai (United Kingdom)), Cornelis J. A. Punt(Radboud University Nijmegen)
British Journal of Cancer
February 26, 1999
10.1038/sj.bjc.6690232
Cited by 16

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k